Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer

Shevchenko,Julia   A.; Khristin,Alexander   A.; Kurilin,Vasily   V.; Kuznetsova,Maria   S.; Blinova,Darya   D.; Starostina,Natalya   M.; Sidorov,Sergey  V.; Sennikov,Sergey   V.

doi:10.3892/or.2019.7435

Autologous dendritic cells and activated cytotoxic T‑cells as combination therapy for breast cancer

Authors:
- Julia A. Shevchenko
- Alexander A. Khristin
- Vasily V. Kurilin
- Maria S. Kuznetsova
- Darya D. Blinova
- Natalya M. Starostina
- Sergey V. Sidorov
- Sergey V. Sennikov
View Affiliations

Affiliations: Federal State Budgetary Institution ‘Research Institute of Fundamental and Clinical Immunology’, Novosibirsk 630099, Russia, Novosibirsk State University, Novosibirsk 630090, Russia
Published online on: December 16, 2019 https://doi.org/10.3892/or.2019.7435
Pages: 671-680

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Breast cancer is the most common oncological pathology in women worldwide. Techniques for improving the clinical parameters of patients undergoing combination therapy for breast cancer are currently under development. A type of treatment employing dendritic cells (DCs) and cytotoxic DC‑induced antigen‑specific T lymphocytes efficiently eliminates residual cancer cells that are the key cause of tumor recurrence and metastasis. In the present study, DCs and activated lymphocytes (treated with IL‑12 and IL‑18) were isolated from the peripheral blood of patients with breast cancer, using a lysate of tumor tissue as antigen. The patients received the cells as part of adjuvant or neoadjuvant regimens (stage IV disease or progression). Evaluation of immunity was performed at 3 and 6 months after terminating immunotherapy. Evaluation of the disease‑free period was performed for 3 years after surgery. The use of antigen‑loaded autologous DCs combined with mononuclear cells with increased cytotoxic activity following Th1 polarization reduced the populations of immunosuppressive cells. The results of the present study demonstrated that the investigated cellular immunotherapy for breast cancer is safe, reduces the risk of relapse and metastasis, and improves immunity by reducing the number of regulatory T cells. Therefore, this therapeutic strategy may represent a novel approach to combating distant metastases of breast cancer.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al: Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 366:2443–2454. 2012. View Article : Google Scholar : PubMed/NCBI
3	Eggermont AM, Kroemer G and Zitvogel L: Immunotherapy and the concept of a clinical cure. Eur J Cancer. 49:2965–2967. 2013. View Article : Google Scholar : PubMed/NCBI
4	Allan CP, Turtle CJ, Mainwaring PN, Pyke C and Hart DN: The immune response to breast cancer, and the case for DC immunotherapy. Cytotherapy. 6:154–163. 2004. View Article : Google Scholar : PubMed/NCBI
5	Fan Z and Zhang Q: Molecular mechanisms of lymphocyte-mediated cytotoxicity. Cell Mol Immunol. 2:259–264. 2005.PubMed/NCBI
6	Reinhard G, Märten A, Kiske SM, Feil F, Bieber T and Schmidt-Wolf IG: Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer. 86:1529–1533. 2002. View Article : Google Scholar : PubMed/NCBI
7	Koski GK, Cohen PA, Roses RE, Xu S and Czerniecki BJ: Reengineering dendritic cell-based anti-cancer vaccines. Immunol Rev. 222:256–276. 2008. View Article : Google Scholar : PubMed/NCBI
8	Palucka K and Banchereau J: Human dendritic cell subsets in vaccination. Curr Opin Immunol. 25:396–402. 2013. View Article : Google Scholar : PubMed/NCBI
9	Gardner A and Ruffell B: Dendritic cells and cancer immunity. Trends Immunol. 37:855–865. 2016. View Article : Google Scholar : PubMed/NCBI
10	Sabado RL, Balan S and Bhardwaj N: Dendritic cell-based immunotherapy. Cell Res. 27:74–95. 2017. View Article : Google Scholar : PubMed/NCBI
11	Tomasicchio M, Semple L, Esmail A, Meldau R, Randall P, Pooran A, Davids M, Cairncross L, Anderson D, Downs J, et al: An autologous dendritic cell vaccine polarizes a Th-1 response which is tumoricidal to patient-derived breast cancer cells. Cancer Immunol Immunother. 68:71–83. 2019. View Article : Google Scholar : PubMed/NCBI
12	Lin M, Liang S, Jiang F, Xu J, Zhu W, Qian W, Hu Y, Zhou Z, Chen J, Niu L, et al: 2003-2013, a valuable study: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in stage IV breast cancer. Immunol Lett. 183:37–43. 2017. View Article : Google Scholar : PubMed/NCBI
13	Gelao L, Criscitiello C, Esposito A, De Laurentiis M, Fumagalli L, Locatelli MA, Minchella I, Santangelo M, De Placido S, Goldhirsch A and Curigliano G: Dendritic cell-based vaccines: Clinical applications in breast cancer. Immunotherapy. 6:349–360. 2014. View Article : Google Scholar : PubMed/NCBI
14	Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM and Matrisian LM: The prioritization of cancer antigens: A national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 15:5323–5337. 2009. View Article : Google Scholar : PubMed/NCBI
15	Benteyn D, Heirman C, Bonehill A, Thielemans K and Breckpot K: mRNA-based dendritic cell vaccines. Expert Rev Vaccines. 14:161–176. 2015. View Article : Google Scholar : PubMed/NCBI
16	Maksyutov AZ, Lopatnikova YA, Kurilin VV, Shevchenko YA, Khantakova YN, Gavrilova EV, Maksyutov RA, Peregudov AG, Zaytsev SA, Kozlov VA and Sennikov SV: Efficiency studies of induced cytotoxic immune response of mononuclear cells by means of dendritic cells transfected by polyepitopic HER2/ERBB2 constructs. Meditsinskaya Immunol. 16:417–424. 2014. View Article : Google Scholar
17	Kuznetsova M, Lopatnikova J, Khantakova J, Maksyutov R, Maksyutov A and Sennikov S: Generation of populations of antigenspecific cytotoxic T cells using DCs transfected with DNA construct encoding HER2/neu tumor antigen epitopes. BMC Immunol. 18:312017. View Article : Google Scholar : PubMed/NCBI
18	Garu A, Moku G, Gulla SK and Chaudhuri A: Genetic immunization with in vivo dendritic cell-targeting liposomal DNA vaccine carrier induces long-lasting antitumor immune response. Mol Ther. 24:385–397. 2016. View Article : Google Scholar : PubMed/NCBI
19	Goyvaerts C and Breckpot K: The journey of in vivo virus engineered dendritic cells from bench to bedside: A bumpy road. Front Immunol. 9:20522018. View Article : Google Scholar : PubMed/NCBI
20	Shevchenko YA, Khristin AA, Falaleeva SA, Kurilin VV, Kuznetsova MS, Sidorov SV and Sennikov SV: Phenotypic and functional characteristics of dendritic cells and contents of suppressor cell populations in peripheral blood of breast cancer patients. Vopr Onkol. 62:519–523. 2016.(In Russian). PubMed/NCBI
21	Thanendrarajan S, Nowak M, Abken H and Schmidt-Wolf IG: Combining cytokine-induced killer cells with vaccination in cancer immunotherapy: More than one plus one? Leuk Res. 35:1136–1142. 2011. View Article : Google Scholar : PubMed/NCBI
22	Gao D, Li C, Xie X, Zhao P, Wei X, Sun W, Liu HC, Alexandrou AT, Jones J, Zhao R and Li JJ: Autologous tumor lysate-pulsed dendritic cell immunotherapy with cytokine-induced killer cells improves survival in gastric and colorectal cancer patients. PLoS One. 9:e938862014. View Article : Google Scholar : PubMed/NCBI
23	Novick D, Kim S, Kaplanski G and Dinarello CA: Interleukin-18, more than a Th1 cytokine. Semin Immunol. 25:439–448. 2013. View Article : Google Scholar : PubMed/NCBI
24	Wawrocki S, Druszczynska M, Kowalewicz-Kulbat M and Rudnicka W: Interleukin-18 (IL-18) as a target for immune intervention. ActaBiochim Pol. 63:59–63. 2016.
25	http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_8.5×11.pdf
26	WHO Handbook for Reporting the Results of Cancer Treatment//World Health Organization 1979. Geneva: WHO Offset Publication. No. 48. https://apps.who.int/iris/handle/10665/37200
27	Huang A, Zhang B, Wang B, Zhang F, Fan KX and Guo YJ: Increased CD14(⁺)HLA-DR (−/low) myeloid-derived suppressor cells correlate with extrathoracic metastasis and poor response to chemotherapy in non-small cell lung cancer patients. Cancer Immunol Immunother. 62:1439–1451. 2013. View Article : Google Scholar : PubMed/NCBI
28	Sennikov SV, Shevchenko JA, Kurilin VV, Khantakova JN, Lopatnikova JA, Gavrilova EV, Maksyutov RA, Bakulina AY, Sidorov SV, Khristin AA and Maksyutov AZ: Induction of an antitumor response using dendritic cells transfected with DNA constructs encoding the HLA-A*02: 01-restricted epitopes of tumor-associated antigens in culture of mononuclear cells of breast cancer patients. Immunol Res. 64:171–180. 2016. View Article : Google Scholar : PubMed/NCBI
29	Shevchenko YA, Khantakova YN, Kurilin VV, Lopatnikova YA, Sidorov SV, Kozlov VA and Sennikov SV: Stimulation of the cytotoxic immune response in the culture of mononuclear cells of patients breast cancer by dendritic cells loaded with antigens of tumor lysates. Immunology. 134:327–330. 2013.
30	Jeras M, Bergant M and Repnik U: In vitro preparation and functional assessment of human monocyte-derived dendritic cells-potential antigen-specific modulators of in vivo immune responses. Transpl Immunol. 14:231–244. 2005. View Article : Google Scholar : PubMed/NCBI
31	Elizalde PV, Cordo Russo RI, Chervo MF and Schillaci R: ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy. Endocr Relat Cancer. 23:T243–T257. 2016. View Article : Google Scholar : PubMed/NCBI
32	Boudreau J, Bonehill A, Thielemans K and Wan Y: Engineering dendritic cells to enhance cancer immunotherapy. Mol Ther. 19:841–853. 2011. View Article : Google Scholar : PubMed/NCBI
33	Willimsky G and Blankenstein T: Sporadic immunogenic tumours avoid destruction by inducing T cell tolerance. Nature. 437:141–146. 2005. View Article : Google Scholar : PubMed/NCBI
34	Bernhard H, Neudorfer J, Gebhard K, Conrad H, Hermann C, Nährig J, Fend F, Weber W, Busch DH and Peschel C: Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother. 57:271–280. 2008. View Article : Google Scholar : PubMed/NCBI
35	Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E and Cardoso F: Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 75:284–298. 2017. View Article : Google Scholar : PubMed/NCBI
36	Zhan HL, Gao X, Pu XY, Li W, Li ZJ, Zhou XF and Qiu JG: A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma. Chin Med J (Engl). 125:3771–3777. 2012.PubMed/NCBI
37	Marmé F: Immunotherapy in Breast Cancer. Oncol Res Treat. 39:335–345. 2016. View Article : Google Scholar : PubMed/NCBI
38	Palucka AK, Ueno H, Connolly J, Kerneis-Norvell F, Blanck JP, Johnston DA, Fay J and Banchereau J: Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8⁺ T-cell immunity. J Immunother. 29:545–557. 2006. View Article : Google Scholar : PubMed/NCBI
39	Lowenfeld L, Mick R, Datta J, Xu S, Fitzpatrick E, Fisher CS, Fox KR, DeMichele A, Zhang PJ, Weinstein SP, et al: Dendritic cell vaccination enhances immune responses and induces regression of HER2(pos) DCIS independent of route: Results of randomized selection design trial. Clin Cancer Res. 23:2961–2971. 2017. View Article : Google Scholar : PubMed/NCBI
40	Kuznetsova M, Lopatnikova J, Shevchenko J, Silkov A, Maksyutov A and Sennikov S: Cytotoxic activity and memory T cell subset distribution of in vitro-stimulated CD8⁺ T cells specific for HER2/neu epitopes. Front Immunol. 10:10172019. View Article : Google Scholar : PubMed/NCBI
41	Nishikawa H and Sakaguchi S: Regulatory T cells in cancer immunotherapy. Curr Opin Immunol. 27:1–7. 2014. View Article : Google Scholar : PubMed/NCBI
42	Nishikawa H and Sakaguchi S: Regulatory T cells in tumor immunity. Int J Cancer. 127:759–767. 2010.PubMed/NCBI